Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenvatinib in Combination with Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Next Previous
Search
Trial Profile

Lenvatinib in Combination with Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Squamous cell cancer; Thyroid cancer
  • Focus Therapeutic Use

Most Recent Events

  • 24 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 20 Jul 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2025.
  • 20 Jul 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top